Interview With Lauren E. Bigham, PhD: The Psychosocial Needs of Patients Receiving CAR T-Cell Therapy, Part 1

Interview with Liza Rodriguez, DNP, E-MBA, APRN, AOCNP: Survivorship Care Post CAR T-Cell Therapy

Interview with Liza Rodriguez, DNP, E-MBA, APRN, AOCNP: Telemedicine for Patients Receiving CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Sarah Jimenez, DNP, AGACNP-BC, AOCNP BMT/IEC Advanced Practice Provider Blood and Marrow Transplantation/Immune Effector Cell Therapy Program Augusta University/Georgia Cancer Center	Liza Rodriguez, DNP, E-MBA, APRN, AOCNP APP Manager Hematology/Blood and Marrow Transplant Program APP Council Chair Division of Hematologic Malignancies and Cellular Therapeutics The University of Kansas Cancer Center

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

Lymphoma Research Foundation: Treatment Options: CAR T-Cell Therapy

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive too

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

CAR T-Cell Therapy Resource Center

Interview With Lauren E. Bigham, PhD: The Psychosocial Needs of Patients Receiving CAR T-Cell Therapy, Part 1

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

Lymphoma Research Foundation: Treatment Options: CAR T-Cell Therapy

Science Advances

Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive too

Blood

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Blood Advances

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Nature Medicine

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

Blood Advances

EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients post CD19-CAR T cell therapy

Blood Advances

Access barriers to anti-CD19+ CAR T-cell therapy for NHL across a community transplant and cellular therapy network

Blood Advances

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

JAMA Network Open

Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets